Black Diamond Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| BB BIOTECH AG | — | Purchase | 172,974 | $2.18 | $377,083 | 5,278,038 | Oct 27, 2022 |
| BB BIOTECH AG | — | Purchase | 87,850 | $1.51 | $132,654 | 4,913,386 | Oct 21, 2022 |
| BB BIOTECH AG | — | Purchase | 53,734 | $1.42 | $76,302 | 4,825,536 | Oct 19, 2022 |
| Behbahani Ali | — | Award / Grant | 4,532 | $2.62 | $11,874 | 20,087 | Sep 16, 2022 |
| DIXON WENDY L | — | Award / Grant | 4,103 | $2.62 | $10,750 | 9,049 | Sep 16, 2022 |
| Velleca Mark A. | — | Award / Grant | 4,294 | $2.62 | $11,250 | 12,733 | Sep 16, 2022 |
| INGRAM ROBERT ALEXANDER | — | Award / Grant | 6,584 | $2.62 | $17,250 | 33,479 | Sep 16, 2022 |
| Ni Fang | SEE REMARKS | Purchase | 25,000 | $2.44 | $61,000 | 69,026 | Jun 29, 2022 |
| DIXON WENDY L | — | Award / Grant | 4,946 | $2.03 | $10,040 | 4,946 | Jun 17, 2022 |
| Behbahani Ali | — | Award / Grant | 5,850 | $2.03 | $11,875 | 15,555 | Jun 17, 2022 |
| Velleca Mark A. | — | Award / Grant | 5,542 | $2.03 | $11,250 | 8,439 | Jun 17, 2022 |
| DIXON WENDY L | — | Award / Grant | 4,060 | $2.03 | $8,242 | 4,060 | Jun 17, 2022 |
| INGRAM ROBERT ALEXANDER | — | Award / Grant | 8,498 | $2.03 | $17,251 | 26,895 | Jun 17, 2022 |
| BIOTECH GROWTH N V | — | Purchase | 150,000 | $2.66 | $399,000 | 4,438,402 | Apr 28, 2022 |
| BIOTECH GROWTH N V | — | Purchase | 150,000 | $3.24 | $486,000 | 4,288,402 | Apr 18, 2022 |
| BIOTECH GROWTH N V | — | Purchase | 150,000 | $3.42 | $513,000 | 3,885,846 | Apr 13, 2022 |
| Behbahani Ali | — | Award / Grant | 4,346 | $3.02 | $13,125 | 9,705 | Mar 18, 2022 |
| Velleca Mark A. | — | Award / Grant | 2,897 | $3.02 | $8,749 | 2,897 | Mar 18, 2022 |
| INGRAM ROBERT ALEXANDER | — | Award / Grant | 5,795 | $3.02 | $17,501 | 18,397 | Mar 18, 2022 |
| Jones Erika | SEE REMARKS | Award / Grant | 5,075 | — | — | 5,075 | Feb 15, 2022 |
| Behbahani Ali | — | Award / Grant | 2,472 | $5.31 | $13,126 | 5,359 | Dec 17, 2021 |
| INGRAM ROBERT ALEXANDER | — | Award / Grant | 3,296 | $5.31 | $17,502 | 12,602 | Dec 17, 2021 |
| Behbahani Ali | — | Award / Grant | 1,326 | $9.90 | $13,127 | 2,887 | Sep 17, 2021 |
| INGRAM ROBERT ALEXANDER | — | Award / Grant | 1,869 | $9.90 | $18,503 | 9,306 | Sep 17, 2021 |
| Behbahani Ali | — | Award / Grant | 1,014 | $12.95 | $13,131 | 1,561 | Jun 18, 2021 |
| INGRAM ROBERT ALEXANDER | — | Award / Grant | 1,255 | $12.95 | $16,252 | 7,437 | Jun 18, 2021 |
| Shah Rajeev M. | — | Other | 443 | $24.01 | $10,636 | — | May 20, 2021 |
| Hatzis-Schoch Brent | See Remarks | Sale | 351 | $28.20 | $9,898 | 8,400 | May 12, 2021 |
| Roberts Christopher D. | Chief Scientific Officer | Sale | 2,500 | $26.64 | $66,600 | 3,200 | May 3, 2021 |
| Hatzis-Schoch Brent | See Remarks | Sale | 4,078 | $25.00 | $101,950 | 8,400 | Apr 12, 2021 |
| Roberts Christopher D. | Chief Scientific Officer | Option Exercise | 2,500 | $10.86 | $27,150 | 5,700 | Apr 5, 2021 |
| Shah Rajeev M. | — | Other | 353,814 | $24.26 | $8,583,528 | 2,277,978 | Apr 1, 2021 |
| Behbahani Ali | — | Award / Grant | 547 | $24.01 | $13,133 | 547 | Mar 18, 2021 |
| Shah Rajeev M. | — | Award / Grant | 443 | $24.01 | $10,636 | 443 | Mar 18, 2021 |
| INGRAM ROBERT ALEXANDER | — | Award / Grant | 677 | $24.01 | $16,255 | 6,182 | Mar 18, 2021 |
| Hatzis-Schoch Brent | See Remarks | Sale | 4,078 | $26.36 | $107,496 | 8,400 | Mar 12, 2021 |
| Roberts Christopher D. | Chief Scientific Officer | Sale | 884 | $26.57 | $23,488 | 3,200 | Mar 3, 2021 |
| Hatzis-Schoch Brent | See Remarks | Sale | 307 | $27.66 | $8,492 | 8,400 | Feb 12, 2021 |
| Roberts Christopher D. | Chief Scientific Officer | Option Exercise | 2,500 | $10.86 | $27,150 | 5,700 | Feb 3, 2021 |
| Hatzis-Schoch Brent | See Remarks | Sale | 1,669 | $30.50 | $50,905 | 16,261 | Jan 12, 2021 |
| Leggett Thomas | Chief Financial Officer | Sale | 3,000 | $33.94 | $101,820 | — | Jan 8, 2021 |
| Roberts Christopher D. | Chief Scientific Officer | Sale | 1,963 | $31.31 | $61,462 | 3,737 | Jan 4, 2021 |
| Epstein David M. | See Remarks | Sale | 9,985 | $30.99 | $309,435 | 698,438 | Jan 4, 2021 |
| Hatzis-Schoch Brent | See Remarks | Option Exercise | 5,400 | $3.20 | $17,280 | 8,400 | Dec 28, 2020 |
| INGRAM ROBERT ALEXANDER | — | Award / Grant | 505 | $34.29 | $17,316 | 5,505 | Dec 15, 2020 |
| Roberts Christopher D. | Chief Scientific Officer | Option Exercise | 3,200 | $10.86 | $34,752 | 3,200 | Dec 15, 2020 |
| Epstein David M. | See Remarks | Option Exercise | 2,500 | $6.42 | $16,050 | 705,423 | Dec 15, 2020 |
| Hatzis-Schoch Brent | See Remarks | Option Exercise | 4,078 | $3.20 | $13,050 | 7,078 | Dec 14, 2020 |
| Versant Vantage I, L.P. | — | Other | 310 | — | — | — | Dec 14, 2020 |
| Bolzon Bradley J PhD | — | Other | 11 | — | — | 21,851 | Dec 14, 2020 |